T.MAN Pharmaceutical Public Company Limited
10.30
THB
0.00
(0.00%)
ISIN
THC209010006
Return %
Stock
S&P 500
1Y
-9.65
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
THB
•
in mil. unless spec.Working Capital
THB
•
in mil. unless spec.Growth Rates
THB
•
in mil. unless spec.Quarterly Revenue
THB
•
in mil. unless spec.Quarterly Earnings Per Share
THB
•
in mil. unless spec.Quarterly Dividends Per Share
THB
•
in mil. unless spec.Company Description
- CEO
- Praphon Thanachotphan
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Bangkok Thailand
- IPO Date
- Oct 22, 2024
- Website
- tmanpharma.in.th
- Similar Companies
- Business
- T.MAN Pharmaceutical Public Company Limited is a Thailand-based healthcare and pharmaceutical manufacturer and distributor engaged in the research, development, production, and marketing of pharmaceuticals, herbal medicines, dietary supplements, cosmeceuticals, and medical supplies. The company operates through two primary business streams: proprietary brand commercialization and contract manufacturing (OEM/ODM) services for third-party brand owners. Its comprehensive product portfolio encompasses modern ethical and over-the-counter pharmaceuticals, including analgesics, antipyretics, anti-inflammatory agents, antibiotics, respiratory remedies, gastrointestinal medications, antihistamines, and topical antifungal and dermatological treatments sold under established brands such as Propoliz, Myda, and IBUMAN; herbal and traditional medicines, including Andrographis paniculata preparations, botanical cough syrups, and therapeutic balms; dietary supplements and nutraceuticals, featuring multivitamins, minerals, collagen supplements, and targeted immune-support formulations; cosmeceuticals and personal care products, comprising specialized dermatological cleansers, acne solutions, and oral health formulations; and medical devices and clinical supplies, including rapid diagnostic test kits, disinfectants, and healthcare consumables. Through its integrated subsidiaries, including Nova Health Co., Ltd., Nature Science Co., Ltd., and T.Man Trading Co., Ltd., the company delivers turnkey OEM/ODM services spanning formulation research, regulatory compliance, quality control, stability testing, and large-scale manufacturing in compliance with international PIC/S Good Manufacturing Practice (GMP) standards. T.MAN Pharmaceutical serves an extensive distribution network that includes state and private hospital systems, medical clinics, modern trade retailers, national pharmacy chains, independent drugstores, convenience store networks, and online marketplaces, alongside export operations across Southeast Asia and the broader Asia-Pacific region. Founded in 1972 and headquartered in Bangkok, Thailand, the company recently completed its initial public offering on the Stock Exchange of Thailand in October 2024 to finance the construction of advanced solid and liquid dosage production lines, the installation of automated warehouse facilities, the expansion of biotechnology and formulation research laboratories, and the acceleration of international market penetration.